Research use only. This page is education, not medical or legal advice. Eloralintide is an investigational drug that no regulator has approved.

Is eloralintide FDA-approved?

No. Eloralintide (LY3841136) is investigational. Eli Lilly has moved it into Phase 3-stage studies following a positive Phase 2 readout, but it has not been submitted for, or granted, FDA approval, and it is not approved by any other regulatory body. On public ClinicalTrials.gov timelines, the lead Phase 3 trials estimate primary completion between January and June 2028, which would put a filing and standard review no earlier than 2029.

Can you buy eloralintide right now?

No. There is no approved commercial supply chain for eloralintide anywhere in the world. It is only available to participants enrolled in registered clinical trials. Any product marketed online as “eloralintide” for personal purchase or self-administration should be treated with significant caution — independent testing of similar research-market peptide vials has repeatedly found measured content diverging from label claims, and a certificate of analysis shows what a lab measured in one sample, not equivalence to Lilly’s trial drug.

Is eloralintide a GLP-1 drug?

No. Eloralintide is a selective amylin receptor agonist — it does not activate the GLP-1 receptor at all. Semaglutide, tirzepatide, and retatrutide work through GLP-1 (and in tirzepatide’s and retatrutide’s case, additional) receptor pathways. Lilly is studying eloralintide combined with tirzepatide precisely because the two drugs work through different mechanisms.

What is eloralintide used for?

In its current trials, eloralintide is being studied for weight management in adults with obesity or overweight, for type 2 diabetes in combination with tirzepatide, and separately for obstructive sleep apnea (NCT07369011) and knee osteoarthritis pain. It is not approved for any use outside of these registered clinical trials.

How does eloralintide differ from semaglutide or tirzepatide?

Semaglutide is a GLP-1 receptor agonist, and tirzepatide is a dual GIP/GLP-1 receptor agonist. Eloralintide works through an entirely different receptor system, as a selective agonist of the amylin receptor (primarily AMY1R, with roughly 10-fold selectivity over AMY3R). Eli Lilly has said eloralintide’s mechanism differs from tirzepatide’s and is studying both as standalone therapies and in combination under the “EloraTZP” program, which reported a -23.3% weight change in people with type 2 diabetes.

How does eloralintide differ from cagrilintide?

Both are amylin-class compounds, but eloralintide is selective for the AMY1 receptor, while cagrilintide activates both the amylin and calcitonin receptors. Eloralintide’s reported half-life (12.9–15.3 days) is also roughly double cagrilintide’s, though both are still dosed once weekly in every published trial. See our full comparison page for trial-by-trial detail.

What were the Phase 2 trial results?

Eli Lilly’s Phase 2 trial (NCT06230523) reported efficacy-estimand mean weight reductions of 9.5% to 20.1% across active-dose arms over 48 weeks, versus 0.4% for placebo. All active-dose arms reportedly met the primary endpoint. A separate Phase 2b combination trial with tirzepatide reported -23.3% weight change in people with type 2 diabetes. See our trial dosage page for the dose-by-dose breakdown.

Does eloralintide cause 30% weight loss?

Not in any published trial. The best verified figures are about -20% at 48 weeks on the top dose arm (phase 2, on treatment) and -23.3% for the eloralintide-plus-tirzepatide combination in people with type 2 diabetes. Numbers near or above 30% circulating online are not supported by any registered eloralintide trial we could find; they may be mixing up a different drug’s data or a cherry-picked analysis method.

What side effects has eloralintide shown?

The most commonly reported adverse events in the Phase 2 trial were mild to moderate nausea (11%–64% by arm) and fatigue (0%–46%), with about 10% of participants stopping treatment because of an adverse event. A smaller Phase 1b study also reported mood-related events in four participants at higher doses. See our side effects page for full detail.

Is eloralintide safe long-term?

Unknown. The longest published human exposure is 48 weeks, in a few hundred people. The lead Phase 3 trials are registered to run through 2030, and questions about bone health, lean mass, mood, and weight regain after stopping treatment don’t yet have published answers.

When might eloralintide become available?

There is no public timeline for approval or commercial availability. Lilly has registered Phase 3-stage studies (NCT07369011, NCT07701083, and five ENLIGHTEN-branded obesity trials) following its November 2025 Phase 2 readout, with estimated primary completion between January and June 2028. Phase 3 trials, regulatory review, and approval (if granted) typically take multiple years from this stage, putting any realistic approval in 2029 at the earliest. We’ll update this page as new, verifiable information is published.

Who runs this website?

This is an independent, unaffiliated research information resource. It is not operated by, or affiliated with, Eli Lilly and Company, and it does not sell eloralintide or any related product. See our About page for more.

Sources

All sources read and verified October 2026.

• Billings LK, et al. Eloralintide Phase 2. The Lancet 2025. ClinicalTrials.gov NCT06230523.
• Eli Lilly. EloraTZP Phase 2b release, September 30, 2026: PR Newswire.
• Bhattachar S, et al. Diabetes, Obesity and Metabolism 2026. PMC12992164.
• ClinicalTrials.gov, eloralintide (LY3841136) records: search.